Drug Detail

Drug Name Dabrafenib
Trade Name Tafinlar
Synonyms GSK2118436
Drug Descriptions

Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in inhibition of tumor cell proliferation (NCI Drug Dictionary). Tafinlar (dabrafenib) is FDA approved for BRAF V600E positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, and BRAF V600E-mutant anaplastic thyroid cancer (FDA.gov).

DrugClasses BRAF Inhibitor 18

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Dabrafenib + Pazopanib
Cetuximab + Dabrafenib + SCH772984
Dabrafenib + GSK2126458
Dabrafenib + GSK2141795
ABT-263 + CGM097 + Dabrafenib + PF-04217903
AMG 232 + Trametinib + Dabrafenib
Dabrafenib + Trametinib + PDR001
Cetuximab + Dabrafenib
Dabrafenib + SCH772984
Pembrolizumab + Dabrafenib
Dabrafenib + Trametinib + Metformin
Panitumumab + Dabrafenib
Dabrafenib + Digoxin + Trametinib
Trametinib + Dabrafenib + Navitoclax
Cetuximab + Dabrafenib + Trametinib
Dabrafenib + Selumetinib
Trametinib + Dabrafenib
Dabrafenib + Ipilimumab + Trametinib
Altiratinib + Dabrafenib
Dabrafenib + Nivolumab + Trametinib
Dabrafenib + Everolimus + Trametinib
Dabrafenib + SCH772984 + Trametinib
AT13387 + Dabrafenib + Trametinib
Dabrafenib + Trametinib + GSK2141795
Dabrafenib + Rosuvastatin + Midazolam
ABT-263 + Alpelisib + Dabrafenib + Erlotinib
Dabrafenib + Gefitinib
Dabrafenib + Trametinib + MCS110
Dabrafenib + Durvalumab + Trametinib
Dabrafenib + INCB039110 + Trametinib
Dabrafenib + Lapatinib
Panitumumab + Trametinib + Dabrafenib
Dabrafenib + Ipilimumab
Pembrolizumab + Dabrafenib + Trametinib
Dabrafenib + Trametinib + Phenformin
talimogene laherparepvec + Dabrafenib + Trametinib
Dabrafenib Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in inhibition of tumor cell proliferation (NCI Drug Dictionary). Tafinlar (dabrafenib) is FDA approved for BRAF V600E positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, and BRAF V600E-mutant anaplastic thyroid cancer (FDA.gov).
Dabrafenib + Rabeprazole + Rifampin